Holen Sie sich die Stockscreener-App
0.783
7.26%
0.053
Handel nachbörslich:
.76
-0.023
-2.94%
Schlusskurs vom Vortag:
$0.73
Offen:
$0.7311
24-Stunden-Volumen:
132.00K
Relative Volume:
0.69
Marktkapitalisierung:
$91.46M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-70.78M
KGV:
-1.3982
EPS:
-0.56
Netto-Cashflow:
$-61.27M
1W Leistung:
-1.31%
1M Leistung:
+7.00%
6M Leistung:
-53.67%
1J Leistung:
-65.51%
1-Tages-Spanne:
$0.73
$0.7926
1-Wochen-Bereich:
$0.6937
$0.8476
52-Wochen-Spanne:
$0.66
$3.09
Nautilus Biotechnology Inc Stock (NAUT) Company Profile
Firmenname
Nautilus Biotechnology Inc
Sektor
Branche
Telefon
206-333-2001
Adresse
2701 EASTLAKE AVE EAST, SEATTLE
Vergleichen Sie NAUT mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
NAUT
Nautilus Biotechnology Inc
|
0.783 | 91.46M | 0 | -70.78M | -61.27M | -0.56 |
|
VRTX
Vertex Pharmaceuticals Inc
|
457.03 | 115.95B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
547.74 | 56.52B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
329.77 | 39.44B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
545.11 | 35.14B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
244.32 | 28.51B | 3.81B | -644.79M | -669.77M | -6.24 |
Nautilus Biotechnology Inc Stock (NAUT) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2024-12-05 | Herabstufung | Goldman | Neutral → Sell |
| 2024-06-27 | Eingeleitet | Guggenheim | Buy |
| 2024-06-03 | Fortgesetzt | Jefferies | Hold |
| 2022-01-06 | Eingeleitet | Morgan Stanley | Equal-Weight |
| 2021-11-02 | Eingeleitet | Cowen | Outperform |
| 2021-08-04 | Eingeleitet | Goldman | Neutral |
| 2021-07-13 | Eingeleitet | Jefferies | Buy |
Alle ansehen
Nautilus Biotechnology Inc Aktie (NAUT) Neueste Nachrichten
Millennium Management LLC Purchases Shares of 37,704 Nautilus Biotechnology, Inc. (NASDAQ:NAUT) - Defense World
Millennium Management LLC Has $171,000 Position in Codexis, Inc. (NASDAQ:CDXS) - Defense World
26,324 Shares in Nautilus Biotechnology, Inc. (NASDAQ:NAUT) Purchased by Squarepoint Ops LLC - Defense World
Home Product Center Public (OTCMKTS:HPCRF) Trading Up 20.5% – Should You Buy? - Defense World
Nautilus Biotechnology, Inc. (NASDAQ:NAUT) Shares Bought by Jane Street Group LLC - Defense World
Citadel Advisors LLC Raises Holdings in Nautilus Biotechnology, Inc. (NASDAQ:NAUT) - Defense World
Tenpoint Therapeutics Ltd. Appoints Melissa Epperly as Chief Financial Officer - Business Wire
Northern Trust Corp Sells 32,695 Shares of Nautilus Biotechnology, Inc. (NASDAQ:NAUT) - Defense World
Nautilus Biotechnology to Participate in the Goldman Sachs 46th Annual Global Healthcare Conference - GlobeNewswire
20,256 Shares in Nautilus Biotechnology, Inc. (NASDAQ:NAUT) Purchased by Cubist Systematic Strategies LLC - Defense World
Nautilus Biotechnology, Inc. (NASDAQ:NAUT) Shares Acquired by Dimensional Fund Advisors LP - Defense World
Nautilus Biotechnology And 2 Other Penny Stocks With Promising Potential - Yahoo Finance
Insiders continue to buy Nautilus Biotechnology, Inc. (NASDAQ:NAUT) and now own 31% shares - simplywall.st
Nautilus Biotechnology chief scientist buys $9,885 in common stock By Investing.com - Investing.com Nigeria
Hsbc Holdings PLC Has $92,000 Position in Nautilus Biotechnology, Inc. (NASDAQ:NAUT) - Defense World
Barclays PLC Buys 19,030 Shares of Nautilus Biotechnology, Inc. (NASDAQ:NAUT) - Defense World
Nautilus Biotechnology chief scientist buys $9,885 in common stock - Investing.com
Nautilus Biotechnology Co-founder and Chief Scientist Parag Mallick, Ph.D., Honored with the Academy for Radiology and Biomedical Imaging Research’s Distinguished Investigator Award - Barchart.com
Renaissance Technologies LLC Acquires 95,521 Shares of Nautilus Biotechnology, Inc. (NASDAQ:NAUT) - Defense World
JPMorgan Chase & Co. Raises Stake in Nautilus Biotechnology, Inc. (NASDAQ:NAUT) - Defense World
Nautilus Biotechnology, Inc. (NASDAQ:NAUT) Short Interest Update - Defense World
Nautilus Biotechnology, Inc. (NASDAQ:NAUT) Q1 2025 Earnings Call Transcript - Insider Monkey
Nautilus Biotechnology Reports Q1 2025 Financial Results - TipRanks
Nautilus Biotechnology targets late 2026 platform launch amid proteoform assay advancements - MSN
Nautilus Biotech’s Earnings Call Highlights Progress and Promise - TipRanks
Nautilus Biotechnology Reports First Quarter 2025 Financial Results - GlobeNewswire
Earnings call transcript: Nautilus Biotechnology Q1 2025 surprises with EPS beat - Investing.com
Nautilus Biotechnology (NAUT) Anticipates Tau Proteoform Assay L - GuruFocus
Nautilus Biotechnology Posts Qtrly Loss Per Share $0.13 - marketscreener.com
Nautilus Biotechnology (NAUT) Expected to Announce Quarterly Earnings on Tuesday - American Banking and Market News
Nautilus Biotechnology (NAUT) to Release Earnings on Tuesday - Defense World
Nautilus Biotechnology Inc expected to post a loss of 15 cents a shareEarnings Preview - TradingView
Short Interest in Nautilus Biotechnology, Inc. (NASDAQ:NAUT) Increases By 20.5% - Defense World
Wells Fargo & Company MN Sells 12,607 Shares of Commercial Metals (NYSE:CMC) - Defense World
Nautilus Biotechnology to Announce First Quarter 2025 Financial Results on April 29, 2025 - The Manila Times
Nautilus Biotechnology Appoints Mass Spectrometry Leader Ken Suzuki as Chief Marketing Officer - MarketScreener
NAUT Stock Plummets to 52-Week Low at $0.82 Amid Market Turbulence By Investing.com - Investing.com South Africa
NAUT Stock Plummets to 52-Week Low at $0.82 Amid Market Turbulence - Investing.com India
Nautilus Biotechnology, Inc. (NASDAQ:NAUT) Stock Position Decreased by Charles Schwab Investment Management Inc. - Defense World
Virtu Financial LLC Takes $28,000 Position in Nautilus Biotechnology, Inc. (NASDAQ:NAUT) - Defense World
We're Keeping An Eye On Nautilus Biotechnology's (NASDAQ:NAUT) Cash Burn Rate - Yahoo Finance
Nautilus Biotechnology: Hold Rating Amid Delayed Launch and Strategic Adjustments - TipRanks
Nautilus Biotechnology’s Earnings Call: Progress Amid Challenges - TipRanks
Nautilus Biotechnology, Inc. (NASDAQ:NAUT) Q4 2024 Earnings Call Transcript - Insider Monkey
Nautilus Biotechnology lays off 16% of workforce, plans release of commercial platform in 2026 - MSN
Nautilus: Trading Below An Albeit Lower Net Cash Figure (NASDAQ:NAUT) - Seeking Alpha
Guggenheim cuts Nautilus Biotech target to $2.50, keeps buy rating - Investing.com
Finanzdaten der Nautilus Biotechnology Inc-Aktie (NAUT)
Umsatz
Nettogewinn
Free Cashflow
ENV
Nautilus Biotechnology Inc-Aktie (NAUT) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Mallick Parag | Chief Scientist |
May 08 '25 |
Buy |
0.73 |
12,000 |
8,788 |
20,491,892 |
| Mallick Parag | Chief Scientist |
May 12 '25 |
Buy |
0.73 |
1,500 |
1,098 |
20,493,392 |
| Patel Sujal M | CEO, President, and Secretary |
Mar 19 '25 |
Buy |
0.99 |
53,300 |
53,028 |
10,117,788 |
| Patel Sujal M | CEO, President, and Secretary |
Mar 20 '25 |
Buy |
1.00 |
23,933 |
23,890 |
10,141,721 |
1.45%
0.86%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):